Rosuvor

Primary hypercholesterolaemia & mixed dyslipidaemia (including Fredrickson type IIa, IIb; heterozygous familial hypercholesterolaemia) as an adjunct to diet when response to diet & exercise is inadequate. Primary dysbetalipoproteinaemia (Fredrickson type III hyperlipoproteinaemia) as an adjunct to diet when response to diet & exercise is inadequate. Reduces elevated LDL-C, total-C & triglycerides; increases HDL-C. Homozygous familial hypercholesterolaemia as an adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis). Reduce risk of stroke, MI & arterial revascularization procedures in individuals w/o clinically evident CHD but w/ increased risk of CV disease based on age ≥50 yr in men & ≥60 yr in women, hsCRP ≥2 mg/L & presence of at least 1 additional CV disease risk factor (eg, HTN, low HDL-C, smoking or family history of premature CHD).

Individualized dosage. Statin naive patient or those who switched from another HMG CoA reductase inhibitor Recommended start dose: 5 or 10 mg once daily. Asian patient Consider initiation of therapy w/ 5 mg once daily. Patient w/ c.521CC or c.421AA genotype Max: 20 mg once daily.

May be taken with or without food.

Hypersensitivity. Concomitant use w/ cyclosporin. Active liver disease or unexplained, persistent elevations of serum transaminases. Severe renal impairment (CrCl <30 mL/min).

Dyslipidaemic Agents

C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

POM